SAN FRANCISCO–(BUSINESS WIRE)–Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the ArteraAI Prostate Test (Post-RP) has been included in the updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer (Version 1.2027), as a risk stratification tool for patients experiencing biochemical recurrence (BCR) following radical prostatectomy. Artera’s tests are the only AI-based risk
